Background: Arrythmogenic right ventricular dysplasia (ARVD/C) refers to fibro fatty infiltration replacement of ventricular myocardium especially that of right ventricle. The clinical presentation varies from asymptomatic state to ventricular tachycardia, heart failure and even sudden death. Diagnosis is established using modified ARVD/C taskforce criteria. Among all the various modalities of diagnosis, magnetic resonance imaging (MRI) gives most comprehensive evaluation of both morphological and functional abnormalities in this disease. MRI may not only obviate need for myocardial biopsy but also give insights into the nature of disease like presence of left ventricular myocardial involvement. We present our 2 years experience of ARVD/C patents who were admitted in our center and in whom diagnosis of ARVD/C was supported by excellent MR imaging.

Materials And Methods: This study was conducted by Department of Radiology and Cardiology SKIMS, a tertiary care center for a period of 2 years. Patients with suspected ARVD/C based on clinical, electrophysiological and echocardiographic findings were subjected to MR imaging. Patients were excluded if they had history metallic implants, claustrophobia or were uncooperative. In this study stress was laid on diagnostic role of MRI in ARVD/C.

Results: The median age at presentation was 31 years (range 21-43 years). 80% of patients were males. Most common clinical presentation was palpatations (40%). Syncope was present in 27% and heart failure in 13%. EKG suggestive of ARVD was seen in 87%. Echocardiographic features suggestive of ARVD/C was seen in all 15 patients. Family history of premature sudden death less than 35 years old was present in one patient only. MRI evidence classical for ARVD/C was seen in 80%.

Conclusion: Demographic features and mode of presentation of our patients is consistent with what has been rest of the world. We performed MRI in all patients to increase the specificity of our diagnosis. MR imaging allows a three-dimensional evaluation of the right ventricle and provides the most important anatomic, functional, and morphologic criteria for diagnosis of ARVD/C within one single study. MR imaging appears to be the optimal imaging technique for detection and follow-up of clinically suspected ARVD/C.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809453PMC
http://dx.doi.org/10.1016/j.jsha.2013.03.002DOI Listing

Publication Analysis

Top Keywords

arvd/c
9
ventricular dysplasia
8
tertiary care
8
care center
8
clinical presentation
8
heart failure
8
sudden death
8
diagnosis arvd/c
8
suspected arvd/c
8
patients
6

Similar Publications

Hot Phases Cardiomyopathy: Pathophysiology, Diagnostic Challenges, and Emerging Therapies.

Curr Cardiol Rep

January 2025

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), European Reference Network for Rare, University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy.

Purpose Of Review: Hot phases are a challenging clinical presentation in arrhythmogenic cardiomyopathy (ACM), marked by acute chest pain and elevated cardiac troponins in the absence of obstructive coronary disease. These episodes manifest as myocarditis and primarily affect young patients, contributing to a heightened risk of life-threatening arrhythmias and potential disease progression. This review aims to synthesize recent research on the pathophysiology, diagnostic challenges, and therapeutic management of hot phases in ACM.

View Article and Find Full Text PDF

Artificial Intelligence Advancements in Cardiomyopathies: Implications for Diagnosis and Management of Arrhythmogenic Cardiomyopathy.

Curr Heart Fail Rep

December 2024

Department of Cardiology, Division Heart & Lungs, University Medical Centre Utrecht, University Utrecht, Utrecht, the Netherlands.

Purpose Of Review: This review aims to explore the emerging potential of artificial intelligence (AI) in refining risk prediction, clinical diagnosis, and treatment stratification for cardiomyopathies, with a specific emphasis on arrhythmogenic cardiomyopathy (ACM).

Recent Findings: Recent developments highlight the capacity of AI to construct sophisticated models that accurately distinguish affected from non-affected cardiomyopathy patients. These AI-driven approaches not only offer precision in risk prediction and diagnostics but also enable early identification of individuals at high risk of developing cardiomyopathy, even before symptoms occur.

View Article and Find Full Text PDF

Extended Duration Bridge to Orthotopic Heart Transplant Utilizing the Impella RP Flex.

ASAIO J

December 2024

From the Department of Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.

We present a case of a 56 year old man presenting with cardiogenic shock from isolated right ventricular failure due to arrhythmogenic right ventricular cardiomyopathy who was successfully bridged to heart transplantation after 29 days on an Impella RP Flex right ventricular assist device. This represents the longest reported duration of support with the device to date and highlights the utility of this platform in the management of severe right ventricular failure.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiac magnetic resonance imaging (CMRI) is a noninvasive, highly accurate method for assessing key heart metrics like volume and ejection fraction, essential for diagnosing heart failure.
  • CMRI's advanced imaging techniques, including late gadolinium enhancement, allow for detailed characterization of myocardial tissue, improving diagnostic and prognostic outcomes.
  • This study investigates the effectiveness of CMRI in diagnosing heart failure and arrhythmias, addressing gaps in current knowledge and enhancing clinical practices.
View Article and Find Full Text PDF

Background: No disease-specific therapy currently exists for arrhythmogenic right ventricular cardiomyopathy (ARVC), a progressive cardiogenetic condition conferring elevated risk for ventricular arrhythmias, heart failure, and sudden cardiac death. Emerging gene therapies have the potential to fill this gap. However, little is known about how adults with ARVC, or any other inherited cardiomyopathy or arrhythmia syndrome, appraise the risks and benefits of gene therapy research and which considerations may influence their decisions about clinical trial participation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!